Abstract
Purpose Associations between XRCC1, XRCC3, and ERCC2 gene polymorphism and prognosis have been investigated in several cancers. The aim of this meta-analysis was to assess the prognostic value of XRCC1, XRCC3, and ERCC2 gene polymorphism in hepatocellular carcinoma (HCC). Methods A systematic literature search was performed to identify relevant studies in PubMed, Embase, and the Cochrane library up to December 2018. The prognostic values of XRCC1, XRCC3, and ERCC2 polymorphisms in HCC were estimated using crude HRs with 95% CIs. Results Ten studies involving 2687 patients were included in the quantitative analysis. There were no statistically significant associations between XRCC1 rs1799782 C>T, XRCC1 rs25487 G>A, and ERCC2 rs1799793 G>A polymorphisms and overall survival (OS). OS was significantly longer for the ERCC2 rs13181 CC genotype than for AA (CC vs. AA: HR = 0.33, 95% CI = 0.15–0.72). A significantly lower OS was observed for patients with the CT genotype compared with the CC genotype at XRCC3 rs861539 (CT vs. CC: HR = 1.64, 95% CI = 1.11–2.42). Conclusion The ERCC2 rs13181 A>C polymorphism and XRCC3 rs861539 C>T polymorphism may be predictive markers for prognosis in patients with HCC. Well-designed studies with larger sample sizes are needed to verify our findings.
Highlights
Liver cancer is one of the most common malignancies
Han et al [10] showed that the X-ray cross-complementing group 1 (XRCC) Gln allele and XRCC T allele are related to a poor prognosis in Hepatocellular carcinoma (HCC)
Our meta-analysis showed that there were no statistically significant associations between the XRCC rs25487 G>A polymorphism and the overall survival (OS) (AA vs. GG: HR = 0.97, 95% confidence intervals (CIs) = 0.51–1.87; GA vs. GG: HR = 1.17, 95% CI = 0.95–1.43, Figure 2; AA+GA vs. GG: HR = 1.25, 95% CI = 0.83–1.88)
Summary
Liver cancer is one of the most common malignancies. It was the sixth most commonly diagnosed cancer and the fourth cause of cancer-related death worldwide in 2018 and accounts for approximately 841,000 new cases and 782,000 deaths annually [1]. Polymorphisms in genes involved in DNA repair are likely to play an important role in the prognosis of HCC and are useful factors for determining the Journal of Oncology risk of cancer progression or recurrence. Various genetic factors are predicted to affect treatment efficiency and prognosis in patients with HCC, such as X-ray cross-complementing group 1 (XRCC ), X-ray repair cross-complementing group 3 (XRCC ), and excision repair cross-complementation group 2 (ERCC ). Despite a number of recent studies of the relationships between XRCC , XRCC , and ERCC gene polymorphisms and prognosis in HCC [8,9,10,11,12,13,14,15,16], the results are inconclusive. We performed a meta-analysis to comprehensively assess the correlation between these polymorphisms and prognosis in HCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
